Known hERG inhibitors linked to drug-induced LQTS, such as terfenadine, cisapride, astemizole, and sertindole, have been withdrawn from the market due to their inhibition of hERG channels and the associated side-effects [92]. The gene discussed is KCNH2; the disease is familial long QT syndrome.